Review Article
New Insight into the Treatment of Advanced Differentiated Thyroid Cancer
Table 2
Trials of other targeted therapies in patients with metastatic differentiated thyroid cancer.
| Agent | Celecoxib [17] | Vorinostat [18] | Thalidomide [19] | Lenalidomide [20] | Rosiglitazone [21] | Bexarotene [22] | Selumetinib [23] | Mechanism | COX-2 inhibitor | Histone deacetylase inhibitor | Antiangiogenesis | Antiangiogenesis | RAIU restoration | RAIU restoration | RAIU restoration | enrolled | 32 | 19 | 36 | 25 | 25 | 11 | 12 | Histology (DTC), | 32 | 16 | 28 | 25 | 25 | 11 | 12 | Outcome | RECIST | RECIST | Tumor volume | Tumor volume | Tumor volume | Tumor volume | Tumor volume | CR% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | PR% | 3 | 0 | 18 | 22 | 20 | 0 | 42 | SD% | 3 | 56 | 32 | 44 | 12 | 18 | 17 |
|
|
RAIU: radioactive iodine uptake; COX-2: cyclooxygenase-2; DTC: differentiated thyroid cancer; RECIST: response evaluation criteria in solid Tumors; CR: complete response; PR: partial response; SD: stable disease.
|